The FBXO4 tumor suppressor functions as a barrier to BrafV600E_dependent metastatic melanoma

Molecular and Cellular Biology

Volumn 33, Issue 22, 2013, Pages 4422-4433

  Lee, Eric K ^a,b   Lian, Zhaorui ^a,b   D'Andre, Kurt ^a,b   Letrero, Richard ^b   Sheng, WeiQi ^d   Liu, Shujing ^b   Diehl, J Nathaniel ^a   Pytel, Dariusz ^a,b   Barbash, Olena ^a,b   Schuchter, Lynn ^a   Amaravaradi, Ravi ^a   Xu, Xiaowei ^b   Herlyn, Meenhard ^c   Nathanson, Katherine L ^a,b   Diehl, J Alan ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WISTAR INSTITUTE   (United States)

^d FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN D1; FBXO4 PROTEIN; GLUTAMIC ACID; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DEGRADATION KINETICS; GENE OVEREXPRESSION; GENOTYPE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MELANOMA; METASTATIC MELANOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; UBIQUITINATION; WESTERN BLOTTING;

AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE, TUMOR; CYCLIN D1; F-BOX PROTEINS; GENE DELETION; HUMANS; MELANOMA; MICE; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION;

EID: 84887014270     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00706-13     Document Type: Article

References (54)

1. Chin L. 2003. The genetics of malignant melanoma: lessons from mouse and man. Nat. Rev. Cancer 3:559-570.
2. Chin L, Merlino G, DePinho RA. 1998. Malignant melanoma: modern black plague and genetic black box. Genes Dev. 12:3467-3481.
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949-954.
4. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS. 2003. High frequency of BRAF mutations in nevi. Nat. Genet. 33:19 -20.
5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364:2507- 2516.
6. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363:809-819.
7. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. 2012. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366:707-714.
8. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, Jr, You MJ, DePinho RA, McMahon M, Bosenberg M. 2009. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41:544-552.
9. Gray-Schopfer VC, Cheong SC, Chong H, Chow J, Moss T, Abdel-Malek ZA, Marais R, Wynford-Thomas D, Bennett DC. 2006. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 95:496-505.
10. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. 2005. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720-724.
11. Ackermann J, Frutschi M, Kaloulis K, McKee T, Trumpp A, Beermann F. 2005. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res. 65: 4005-4011.
12. Bennecke M, Kriegl L, Bajbouj M, Retzlaff K, Robine S, Jung A, Arkan MC, Kirchner T, Greten FR. 2010. Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell 18:135-146.
13. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R. 2009. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15:294-303.
14. Ferguson B, Konrad Muller H, Handoko HY, Khosrotehrani K, Beermann F, Hacker E, Soyer HP, Bosenberg M, Walker GJ. 2010. Differential roles of the pRb and Arf/p53 pathways in murine naevus and melanoma genesis. Pigment Cell Melanoma Res. 23:771-780.
15. Goel VK, Ibrahim N, Jiang G, Singhal M, Fee S, Flotte T, Westmoreland S, Haluska FS, Hinds PW, Haluska FG. 2009. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene 28:2289-2298.
16. Kannan K, Sharpless NE, Xu J, O'Hagan RC, Bosenberg M, Chin L. 2003. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc. Natl. Acad. Sci. U. S. A. 100:1221- 1225.
17. Sviderskaya EV, Hill SP, Evans-Whipp TJ, Chin L, Orlow SJ, Easty DJ, Cheong SC, Beach D, DePinho RA, Bennett DC. 2002. p16(Ink4a) in melanocyte senescence and differentiation. J. Natl. Cancer Inst. 94:446- 454.
18. Ibrahim N, Haluska FG. 2009. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu. Rev. Pathol. 4:551-579.
19. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW. 2006. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38:787-793.
20. Sauter ER, Yeo UC, von Stemm A, Zhu W, Litwin S, Tichansky DS, Pistritto G, Nesbit M, Pinkel D, Herlyn M, Bastian BC. 2002. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 62:3200- 3206.
21. Diehl JA, Zindy F, Sherr CJ. 1997. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitinproteasome pathway. Genes Dev. 11:957-972.
22. Lin DI, Barbash O, Kumar KG, Weber JD, Harper JW, Klein-Szanto AJ, Rustgi A, Fuchs SY, Diehl JA. 2006. Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol. Cell 24:355-366.
23. Vaites LP, Lee EK, Lian Z, Barbash O, Roy D, Wasik M, Klein-Szanto AJ, Rustgi AK, Diehl JA. 2011. The Fbx4 tumor suppressor regulates cyclin D1 accumulation and prevents neoplastic transformation. Mol. Cell. Biol. 31:4513-4523.
24. Deshaies RJ, Joazeiro CA. 2009. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 78:399-434.
25. Silverman JS, Skaar JR, Pagano M. 2012. SCF ubiquitin ligases in the maintenance of genome stability. Trends Biochem. Sci. 37:66-73.
26. Aggarwal P, Lessie MD, Lin DI, Pontano L, Gladden AB, Nuskey B, Goradia A, Wasik MA, Klein-Szanto AJ, Rustgi AK, Bassing CH, Diehl JA. 2007. Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Genes Dev. 21:2908-2922.
27. Aggarwal P, Vaites LP, Kim JK, Mellert H, Gurung B, Nakagawa H, Herlyn M, Hua X, Rustgi AK, McMahon SB, Diehl JA. 2010. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell 18: 329-340.
28. Barbash O, Zamfirova P, Lin DI, Chen X, Yang K, Nakagawa H, Lu F, Rustgi AK, Diehl JA. 2008. Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. Cancer Cell 14:68-78.
29. Korcheva VB, Levine J, Beadling C, Warrick A, Countryman G, Olson NR, Heinrich MC, Corless CL, Troxell ML. 2011. Immunohistochemical and molecular markers in breast phyllodes tumors. Appl. Immunohistochem. Mol. Morphol. 19:119-125.
30. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
31. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. 2007. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 21:379-384.
32. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ, Weinberg RA. 1995. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621-630.
33. Cochran AJ, Lu HF, Li PX, Saxton R, Wen DR. 1993. S-100 protein remains a practical marker for melanocytic and other tumours. Melanoma Res. 3:325-330.
34. Magro CM, Crowson AN, Mihm MC. 2006. Unusual variants of malignant melanoma. Mod. Pathol. 19(Suppl 2):S41-S70. doi:10.1038 /modpathol.3800516.
35. Li Y, Hao B. 2010. Structural basis of dimerization-dependent ubiquiti-nation by the SCF(Fbx4) ubiquitin ligase. J. Biol. Chem. 285:13896- 13906.
36. Barbash O, Lee EK, Diehl JA. 2010. Phosphorylation-dependent regulation of SCF(Fbx4) dimerization and activity involves a novel component, 14-3-3epsilon. Oncogene 30:1995-2002.
37. Zeng Z, Wang W, Yang Y, Chen Y, Yang X, Diehl JA, Liu X, Lei M. 2010. Structural basis of selective ubiquitination of TRF1 by SCFFbx4. Dev. Cell 18:214-225.
38. Lee TH, Perrem K, Harper JW, Lu KP, Zhou XZ. 2006. The F-box protein FBX4 targets PIN2/TRF1 for ubiquitin-mediated degradation and regulates telomere maintenance. J. Biol. Chem. 281:759-768.
39. Alt JR, Cleveland JL, Hannink M, Diehl JA. 2000. Phosphorylationdependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 14:3102-3114.
40. Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA. 2009. Main roads to melanoma. J. Transl. Med. 7:86. doi:10.1186/1479-5876-7-86.
41. Martinez P, Thanasoula M, Munoz P, Liao C, Tejera A, McNees C, Flores JM, Fernandez-Capetillo O, Tarsounas M, Blasco MA. 2009. Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice. Genes Dev. 23:2060-2075.
42. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, Wagle N, Sucker A, Sougnez C, Onofrio R, Ambrogio L, Auclair D, Fennell T, Carter SL, Drier Y, Stojanov P, Singer MA, Voet D, Jing R, Saksena G, Barretina J, Ramos AH, Pugh TJ, Stransky N, Parkin M, Winckler W, Mahan S, Ardlie K, Baldwin J, Wargo J, Schadendorf D, Meyerson M, Gabriel SB, Golub TR, Wagner SN, Lander ES, Getz G, Chin L, Garraway LA. 2012. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485:502-506.
43. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D,Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L. 2012. A landscape of driver mutations in melanoma. Cell 150:251-263.
44. Zhou XZ, Perrem K, Lu KP. 2003. Role of Pin2/TRF1 in telomere maintenance and cell cycle control. J. Cell. Biochem. 89:19-37.
45. Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, Lushnikova T, Monni O, Pere H, Tapper J, Tarkkanen M, Varis A, Wasenius VM, Wolf M, Zhu Y. 1999. DNA copy number losses in human neoplasms. Am. J. Pathol. 155:683-694.
46. Nakayama KI, Nakayama K. 2006. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 6:369-381.
47. Song JH, Schnittke N, Zaat A, Walsh CS, Miller CW. 2008. FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias. Leuk. Res. 32:1751-1755.
48. Spruck CH, Strohmaier H, Sangfelt O, Muller HM, Hubalek M, Muller-Holzner E, Marth C, Widschwendter M, Reed SI. 2002. hCDC4 gene mutations in endometrial cancer. Cancer Res. 62:4535-4539.
49. Welcker M, Clurman BE. 2008. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 8:83-93.
50. Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F, Tetsu O. 2006. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS One 1:e128. doi:10.1371/journal.pone .0000128.
51. Pawar SA, Sarkar TR, Balamurugan K, Sharan S, Wang J, Zhang Y, Dowdy SF, Huang AM, Sterneck E. 2010. C/EBPdelta targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression. Proc. Natl. Acad. Sci. U. S. A. 107:9210-9215.
52. Santra MK, Wajapeyee N, Green MR. 2009. F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature 459:722-725.
53. Yu ZK, Gervais JL, Zhang H. 1998. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc. Natl. Acad. Sci. U. S. A. 95:11324-11329.
54. Kanie T, Onoyama I, Matsumoto A, Yamada M, Nakatsumi H, Tateishi Y, Yamamura S, Tsunematsu R, Matsumoto M, Nakayama KI. 2012. Genetic reevaluation of the role of F-box proteins in cyclin D1 degradation. Mol. Cell. Biol. 32:590-605.